Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : EO2002
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Emmecell Announces FDA Acceptance of IND Application for EO2002 in Corneal Edema
Details : The active IND enables Emmecell to initiate a Phase 1 clinical trial designed to assess the tolerability, safety, and efficacy of EO2002 in patients with corneal edema.
Product Name : EO2002
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 22, 2020
Lead Product(s) : EO2002
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable